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Using a site-directed mutagenesis technique we constructed a new feline herpesvirus-1 recombinant strain containing a
deletion in two genes encoding glycoproteins gI and gE. These proteins may have a role in virulence, the establishment of
latency, and viral recurrence as shown in other herpesviruses of the varicella and simplex types. This recombinant was
characterized and used to immunize juvenile cats against virulent virus challenge. Significant protection resulted from
vaccination of cats by the subcutaneous route. q 1995 Academic Press, Inc.
INTRODUCTION fied live FHV-1 vaccines currently licensed by the U.S.
Department of Agriculture prevent the appearance or re-
Feline herpesvirus-1 (FHV-1) is the agent that causes duce the severity of clinical signs after challenge (Davis
feline viral rhinotracheitis (FVR). It was first isolated from and Beckenhauer, 1976; Edwards et al., 1977; Saint-Ge-
infected cats by Crandell and Maurer (1958) in 1957 and rand, 1988; U.S. Department of Agriculture, Animal and
later classified as an alphaherpesvirus by Ditchfield and Plant Health Inspection Service, National Animal Veteri-
Grinyer (1965). The pathobiology of FVR has been re- nary Services Laboratory, 1985), but these neither pre-
viewed (Povey, 1979). Briefly, FVR is a clinically signifi- vent reinfection with a virulent strain nor protect against
cant respiratory disease, limited to the Felidae, that is latent infection (Gaskell and Povey, 1979; Tham and Stu-
diagnosed in 40% of feline viral upper respiratory disease dert, 1987). Thus, vaccinated or recovered animals may
(Gaskell, 1993). Ocular disease, abortion in pregnant act as asymptomatic carriers and spread virulent virus
queens, neurological disorders, and virus generalization, (Gaskell and Povey, 1982). Furthermore, some of these
with mortality reaching 50% in kittens, are also observed licensed vaccines are avirulent when administered sub-
clinically (Bistner et al., 1971; Crandell, 1971; Holzworth, cutaneously, but virulent to cats oronasally (Kruger et al.,
1987; Pedersen, 1988). FHV-1 is similar in size, structure, 1995; Povey, 1979). The modified live vaccines induce
and complexity to the prototypic class D alphaherpesvi- latent infections and are shed upon reactivation, thus
ruses, including pseudorabies virus (PRV), equine her- contributing to the spread of virulent FHV-1 (Gaskell
pesvirus-1, varicella zoster virus (VZV), and bovine her-
and Povey, 1982).
pesvirus-1 (BHV-1) (Audonnet et al., 1990; Lowe et al.,
Moderate similarity between the nucleic and the amino
1987; Spatz and Maes, 1993; Spatz et al., 1994). The
acid sequences of the hundreds of known herpesvirusesFHV-1 genome, mapped by restriction enzyme digestion
has prompted comparative analysis at the genetic leveltechniques, is approximately 134 kb in size and com-
(Roizman et al., 1992). Herpes simplex virus-1 or humanposed of two segments: the long segment (108 kb) and
herpesvirus-1 (HSV-1) has been the prototype for herpes-the short segment (31 kb). The short segment is com-
virus study, and homologous genes in other herpesvirusposed of two 11-kb inverted repeats, bounding 9 kb of
species are now named consistent with an HSV-1 no-unique DNA (Rota et al., 1986; Grail et al., 1991). There
menclature convention (Roizman and Sears, 1993). Thereare two isomeric forms of FHV-1, since each segment
are 11 HSV-1 glycoproteins (Roizman and Sears, 1993).may invert relative to the other (Rota et al., 1986). A hem-
Of these, 6 are known to bear similarity and share aagglutinating virus, FHV-1 is immunoevasive and induces
common genetic localization in FHV-1 (Spatz and Maes,latent infections like other members of the subfamily,
1993; Spatz et al., 1994). These glycoproteins, essentialAlphaherpesvirinae (Banks and Rouse, 1991; Enquist,
and nonessential, endow herpesviruses with virulence1994; Fawl and Roizman, 1994; Fitzpatrick and Bielefeldt-
and the ability to infect both cells in culture and a specificOhmann, 1991; Gillespie et al., 1970; Rock, 1994). Modi-
subset of natural host cells in vivo (Fawl and Roizman,
1994; Fitzpatrick and Bielefeldt-Ohmann, 1991). In addi-
tion, glycoproteins are the primary inducers of both cellu-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (517) 353-4426. lar and humoral immune responses against FHV-1 infec-
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tion in cats (Burgener and Maes, 1988; Limcumpao et deletion and insertion of a cassette that allows constitu-
tive expression of the enzymatic marker b-galactosidaseal., 1991). Glycoproteins gI and gE of HSV-1 are late
proteins and nonessential for virus growth (Roizman and is described below. This is the first example of nonran-
dom mutagenesis with a screen for FHV-1.Sears, 1993). In FHV-1, genes for gI and gE are located
within the unique short genomic segment (Spatz et al.,
1994). The gI gene encodes a 370-amino-acid protein, MATERIALS AND METHODS
while the gE gene encodes a 532-amino-acid protein
Cell culture, bacterial strains, viruses, and plasmids(Spatz et al., 1994).
Glycoproteins gI and gE of FHV-1 are also similar to
Crandell Reese Feline kidney cells (CRFK) and felineglycoproteins gI and gE of BHV-1 and PRV (Spatz et al.,
tracheal cells, obtained from the American Type Culture1994). Because the gI and gE genes of both BHV-1 and
Collection (CCL 94 and CRL 6165, respectively), werePRV are nonessential and associated with neuroviru-
grown in 11 Dulbecco’s modified Eagle medium supple-lence, they have long been studied as potentially im-
mented with 10% heat-inactivated fetal bovine serumportant targets for deletion in the production of modified
(FBS), 100 units/ml streptomycin, and 100 units/ml peni-live virus vaccines (Jacobs et al., 1993a; Van Engelenburg
cillin (BRL-Life Sciences, Gaithersburg, MD) (DM).et al., 1994). Deletion of the gE gene from BHV-1 attenu-
An EMBL-3 clone containing the FHV-1 (strain C-27)ates viral virulence but maintains a strong immunizing
SalI B restriction fragment previously described by Rotapotential. Further deletion of the entire gI gene makes
et al. (1986) was obtained as a laboratory stock. Plasmidthe virus completely avirulent, but reduces immunogenic-
pON249, from which the LacZ cassette was cloned, wasity and its usability as a vaccine (Van Engelenburg et al.,
previously described (Geballe et al., 1986; Marshall et1994). PRV gE deletion strains are used as nonvirulent
al., 1993) and obtained from Dr. Robert Silva (U.S. Depart-marker vaccines. The PRV gE gene has recently been
ment of Agriculture, Avian Disease and Oncology Labora-reviewed in detail (Jacobs, 1994). Mutagenesis of two
tory, East Lansing, MI). Plasmid pBluescript II was pur-residues of gE, valine-125 and cysteine-126, in the PRV
chased from Stratagene. All plasmids were propagatedgenome produces a virus strain that is immunogenic
in Escherichia coli XL-1 blue (Stratagene, La Jolla, CA).and nonvirulent (Jacobs et al., 1993a,b). In infected cell
The virulence of the parent, Solvay strain of FHV-1,cultures, virus plaque size is affected by gE. Small
supplied by the Solvay Animal Health Corp. (Mendotaplaques produced by gE0 PRV strains are evidence that
Heights, MN) was previously characterized (Kruger et al.,gE is involved in the spread of virus from cell to cell
1995).(Dingwell et al., 1994; Zsak et al., 1992).
Mice lethally challenged with HSV-1 after immuniza-
DNA and RNA molecular methodstion with HSV-1 glycoproteins expressed from baculovi-
rus are protected best by gD, gB, and gC. However, both Restriction enzymes, DNA modification enzymes, and
gI and gE induce significant protective immunity against RNases were purchased from various molecular biology
challenge (Ghiasi et al., 1994). Fc fragment binding by a suppliers. All plasmid constructions were verified by DNA
gI–gE complex has been observed in VZV and HSV, but sequencing. Total RNA was isolated as described for the
not PRV or BHV-1 (Yao and Grose, 1994). Fc fragment guanidinium isothiocyanate/CsCl method (Ausubel et al.,
binding may lead to antibody bipolar bridging, a mecha- 1993).
nism for herpesvirus immunoevasion (Banks and Rouse,
1991; Fitzpatrick and Bielefeldt-Ohmann, 1991). In vivo Virus propagation, virion isolation, and viral DNA
gE and gI form a complex that is critically important for isolation
the spread of herpesvirus through increasing orders of
the central nervous system: their lack inhibits the centrip- FHV-1 was propagated in CRFK cells infected at an
m.o.i. of 0.1. Virions were isolated from CRFK cells afteretal traverse of the virus to neuronal sites more distal
from mucosal epithelial cells than second- or third-order complete CPE was observed. Culture supernatants were
clarified by low-speed centrifugation. The supernatantneurons (Enquist et al., 1994; Mulder et al., 1994; Kritas
et al., 1994). was overlaid on a 25% sucrose cushion in phosphate-
buffered saline (PBS) for cotransfection or a 25% potas-The roles of gI and gE in herpesvirus infection remain
unclear. Selection for the TK0 phenotype has been used sium tartrate cushion for the hemagglutination test and
centrifuged at 40,000 g for 2 hr at 47 (Rota et al., 1986).to generate recombinants, but this system is limited ei-
ther to the TK locus or to the TK gene inserted at another The hemagglutination test was described by Gillespie
et al. (1970). High-molecular-weight genomic DNA waslocus (Nunberg et al., 1989). A genetic approach to the
study of FHV-1 with other selective markers is difficult isolated from a proteinase K (50 mg/ml)-digested virion
pellet by formamide denaturation and dialysis against 50because the virus grows very fast in cell culture [72 hr
for complete CPE; before selection is effective (10–14 mM Tris–Cl/0.1 M NaCl for 72 hr, without centrifugation,
phenol/chloroform extraction, or ethanol precipitationdays) all of the cells in culture are dead (Marshall et
al., 1993]. An FHV-1 recombinant generated by targeted (Kupiec et al., 1987).
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Cotransfection and recombinant screening turing gels and blotted to nylon membranes. A digoxi-
genin probe for the Northern blot was prepared by
Donor plasmid (0.95 mg) DNA and purified virulent asymmetric PCR (Saiki et al., 1988).
FHV-1 virion DNA (12 mg) were cotransfected into CRFK
cultures by calcium phosphate precipitation with a glyc- Plaque size measurement
erol shock (Graham and van der Erb, 1973; Lowe et al.,
Plaque-size measurements were performed visually1987). DNA in 450 ml of H2O (18 MV) was mixed with
using a stage micrometer on a Nikon inverted micro-500 ml of 21 HEPES-buffered saline (pH 7.00) (HBS).
scope.CaCl2 was slowly added to a concentration of 125 mM.
The suspension was incubated in the dark at room tem-
One-step growth curveperature for 15 min. Two hundred microliters of this sus-
pension was overlaid on one well of a six-well tissue CRFK cells were counted using a hemacytometer and
culture plate containing CRFK cells plated 12 hr before, plated at a cell density of 333,000 cells per well of two
which had reached 80% confluence, had been washed 24-well plates in 1 ml of DM. The plates were washed
four times with PBS, pH 7.4, and had been refed with 1 one time with PBS, pH 7.4, and one time with DM without
ml of DM. After 4 hr of incubation in 5% CO2 at 377, the 10% FBS. Each well of a plate was inoculated with either
DNA precipitate-containing medium was removed, cells the recombinant strain or the parent strain at an m.o.i.
were washed twice with PBS, and 2 ml of a solution of 3.0 (1 1 106 TCID50/well) and incubated for 1 hr at 377.
containing 11 HBS and 15% glycerol at room tempera- The inoculum was then removed and the wells were
ture was overlaid onto them. After 2 min the overlay was washed three times with DM. After the last wash, 1 ml
removed, the cells were washed twice with PBS, and 4 of DM was added to each well. The first sample was
ml of fresh DM was added. Cells were refed after 12 hr. removed by pipeting at this time; subsequent samples
Transfected cultures were grown until plaques appeared were removed at 5-hr intervals. Samples were frozen at
(24–48 hr) and harvested with a cell scraper and serolog- 0707 until titrated. Virus titers were determined ac-
ical pipet. Cultures were disrupted by sonication, cleared cording to the method of Karber (1931).
by centrifugation, and titrated. Subsequently, serial dilu-
In vivo studiestions of these stocks were plated in six-well tissue cul-
ture plates for screening. Infected cultures were overlaid Specific-pathogen-free (SPF) cats were purchased
with 1.5% low-melting temperature agarose (BRL-Life Sci- from Harlan–Sprague–Dawley Animal Suppliers of Mad-
ences) containing 11 EMEM/10% FBS/200 mg/ml 5- ison, Wisconsin. Cats were housed in individual cages
bromo-4-chloro-3-indolyl-b-D-galactoside. For plaque pu- under conditions of controlled temperature, humidity, and
rification, agarose plugs containing virus were eluted at lighting. Cat groups were isolated in separate contain-
47 in 11 EMEM/10% FBS for 12 hr prior to replating. ment units. All cats were acclimated for 7 days prior to
inoculation with virus. Cats were sedated with ketamine
PCR analysis hydrochloride (10 mg/kg) and acepromazine maleate (0.1
mg/kg) before inoculation and sampling procedures. Fol-PCR detection analysis of parent strain FHV-1 provided
lowing challenge, all cats were examined daily for clinicala means to assay the homogeneity of the recombinant
signs for a period of 14 days. Clinical signs inducedisolate. Primers used were designated RM 94 and RM
by inoculation of FHV-1 and subsequent challenge were95 (RM 94, 5*-GGTCATGTGTAATGTTGACG; RM 95, 5*-
scored as described in the USDA Supplemental AssayGTCTTTGGTTCTGATGAGAG). These primers amplify a
Method 311 (U.S. Department of Agriculture, Animal and478-bp fragment unique to the unique short region of
Plant Health Inspection Service, National Animal Veteri-FHV-1 and deleted specifically in the recombinant.
nary Services Laboratory, 1985; Table 1). All experimentsPrimer concentration was 2.5 mM with 200 mM dNTPs,
were reviewed and approved by the Animal Use Commit-1.5 mM MgCl2 , 0.5 unit Taq polymerase (Perkin–Elmer)
tee at Michigan State University.added. The PCR consisted of 40 cycles of 957–627–727
in a Perkin–Elmer 9600 thermocycler.
RESULTS
Southern blotting and Northern blotting Construction of a feline herpesvirus-1 recombinant
Recombinant feline herpesvirus-1 strain FHVb-gal-DNA was isolated as described above, digested with
restriction enzymes, electrophoresed, and blotted to ny- gIgED resulted from a site-directed double-crossover re-
combination event between donor plasmid pFHVb-gallon membranes by ascending gel chromatography. Ran-
dom hexamer priming was used to prepare a digoxigenin and the FHV-1 parent strain (Fig. 1). A segment of the
FHV-1 parent, 1022 bp in length, was replaced with a(USB, Cleveland, OH)-labeled probe for the Southern blot.
Total RNA was isolated from FHV-1-infected CRFK cul- LacZ cassette included in pFHVb-gal (Marshall et al.,
1993). Removal of the 1022-bp segment deleted 62 aminotures exhibiting CPE and quantitated spectrophotmetri-
cally. RNA was electrophoresed on formaldehyde dena- acids from the carboxy-terminus of the gI protein, the
/ m4484$7563 11-10-95 16:26:17 viral AP-Virology
15RECOMBINANT FHV AS VACCINE FOR FELINE RHINOTRACHEITIS
TABLE 1 diate early promoter, and flanked by SV40 poly(A) addi-
tion and 3* splice acceptor sites, was inserted into thisUSDA Scoring Method for FHV-1a
site (Marshall et al., 1993). CRFK cells turned blue within
Clinical signs Days Score 24 hr of transfection with pFHVb-gal when grown in me-
dia containing the chromogenic substrate X-gal (200 mg/
Fever ml) (data not shown).
103.0 to 103.97F 1 each day
Classically, marker rescue has been used for routine104.0 to 104.97F 2 each day
genetic manipulation of HSV-1 (Balan et al., 1994). As⁄1057F 3 each day
Conjunctivitis such, cotransfection of purified wild-type FHV-1 virion
Serous discharge only 1 to 3 1 DNA and the donor plasmid pFHVb-gal was expected to
⁄4 2 produce FHV-1 deletion mutants that would turn infected
Mucopurulent discharge 1 to 2 2
cells blue in the presence of X-gal upon infection. Five3 to 5 4
wells each of 10 six-well tissue culture plates (one well⁄6 6
Rhinitis was an untransfected control), each containing approxi-
Serous discharge only 1 to 3 1 mately 106 CRFK cells, were cotransfected as described
⁄4 2 under Materials and Methods. Control transfection of
Mucopurulent discharge 1 to 2 2
CRFK cells with 2.4 mg of purified FHV-1 genomic DNA3 to 5 4
yielded 100–200 plaques in one well of a six-well tissue⁄6 6
Sneezing 1 each day culture plate. No decrease in plaque yield was observed
Dyspnea for cotransfection. Because high background levels of b-
Audible rales 2 each day galactosidase produced transiently by transfected
Coughing 2 each day
pFHVb-gal prevented discrete isolation of a recombinantOpen mouth breathing 3 each day
FHV-1, each well was harvested after plaques appeared.Depression
Anorexia 1 each day Serial dilutions from 104 to 102 TCID50 of stocks prepared
Dehydration 1 to 2 3 from each of the 50 primary cultures were used to infect
⁄3 4 CRFK cells on three wells of a six-well plate. These cul-
Hypothermia 997F 2 each day
tures were overlaid and screened for b-gal production.Oral ulcers (linguinal or oral mucosa)
Two blue plaques were found in 1 of the 150 cultures1 ulcer 4 mm 1 to 5 2
6 to 9 3 screened. Pure recombinant FHV-1 derived from one of
⁄10 4 these two plaques was isolated after 12 rounds of plaque
Multiple ulcers 4 mm 1 to 4 3 purification. At this passage no parent strain contamina-
5 to 8 5
tion was detected. Parent strain was passed in parallel⁄9 7
through 12 rounds of plaque purification and used in allUlcer or ulcers 4 mm 1 to 4 5
5 to 8 7
⁄9 9
Salivating 1 each day




a U.S. Department of Agriculture, Animal and Plant Health Inspection
Service, National Animal Veterinary Services Laboratory (1985).
transcriptional promoter for gE, and downstream DNA
encoding 277 of the 334 amino acid residues constituting
gE. The pFHVb-gal plasmid was constructed as follows.
A 1.3-kb BamHI– XbaI fragment was isolated from an
FHV-1 EMBL-3 fl clone containing the SalI B fragment
(Rota et al., 1986) and cloned into the phagemid Blue-
FIG. 1. Construction of the recombinant FHV-1 strain. (a) Diagram of
script II. The resulting plasmid was recleaved with the FHV-1 genome. UL , unique long region; IR , internal repeat (hatched
enzymes EcoRV and SalI, and a 0.95-kb EcoRV–SalI frag- box); US , unique short region; TR , terminal repeat (hatched box). E,
EcoRI restriction site; S, SalI restriction site; and H, HindIII restrictionment also isolated from the FHV-1 EMBL-3 fl clone
site. (b) Expanded view of unique short region. Glycoprotein genescontaining the SalI B fragment was inserted into this site.
are depicted as boxes. ap, location of the asymmetric probe used forFinally, the construct was linearized at a unique PstI
exclusion of the wild-type strain and Northern blotting. (c) Location of
site located between the two FHV-1 fragments. A LacZ restriction fragments used to construct donor plasmid aligned at their
cassette containing the E. coli b-galactosidase gene, corresponding positions in the unique short region. Restriction sites are
shown above. (d) LacZ cassette, arrow shows direction of transcription.transcriptionally controlled by the cytomegalovirus imme-
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rated on a 1% agarose (FMC LE) gel by electrophoresis
(data not shown). A Southern blot was prepared, hybrid-
ized with digoxigenin-labeled pFHVb-gal, and developed
(Fig. 3). The pFHVb-gal probe can hybridize both to FHV-
1 sequences (gD, gI, and gE) and to the LacZ cassette,
but not to the deleted segment (Fig. 1). As expected,
hybridization of pFHVb-gal (1) to an EcoRI digest of par-FIG. 2. PCR assay used to exclude the parent strain from prepara-
tions of FHVDgIgEbgal. Agarose (1%) electrophoresis of PCR products ent strain virion DNA disclosed two bands of 4.3 and 8.2
from reactions with increasing dilutions of purified parent strain DNA kb (Fig. 3, lane 1), (2) to a HindIII digest of parent strain
as template and from purified recombinant DNA isolated from CRFK DNA revealed one band of 31 kb (Fig. 3, lane 3), and (3)
cells infected with the 12th and 13th passage of the recombinant. (Lane
to a SalI digest of parent strain DNA yielded one band1) fx cut with HaeIII. Lanes 2 –10 contain amplified genomic virion
of 13 kb (Fig. 3, lane 5) as depicted in Fig. 1. AssumingDNA from the parent strain: (lane 2) 4 1 108 genome equivalents, (lane
3) 4 1 106 genome equivalents, (lane 4) 4 1 104 genome equivalents, that one copy of the 5422-bp LacZ expression cassette
(lane 5) 4 1 102 genome equivalents, (lane 6) 4 genome equivalents, replaced the 1022-bp BamHI–EcoRV gI–gE encoding
(lane 7) 4 1 1002 genome equivalents, (lane 8) 4 1 1004 genome segment of the parent, the recombinant genome length
equivalents, (lane 9) 4 1 1006 genome equivalents, (lane 10) 4 1 1008
would increase by 4.4 kb and this is indeed the case.genome equivalents, (lane 11) blank. Lanes 12 and 13 contain amplified
Hybridization of pFHVbgal (1) to an EcoRI digest of re-virion genomic DNA from the recombinant strain: (lane 12) 4 1 108
genome equivalents, (lane 13) 4 1 108 genome equivalents. PCR reac- combinant strain virion DNA revealed one extra band
tion yields a 478-bp product. (4.4 kb) and increased the size of one of the bands (5.1
kb) present in the wild-type digest (Fig. 3, lane 2), (2) to
a HindIII digest disclosed one additional band with a
subsequent analysis as a control. No genomic re-
total size increase of 4.4 kb, and (3) to a SalI digest
arrangements were observed at this passage by restric-
yielded an increase in size of the single band of 4.4 kb.
tion enzyme analysis (data not shown).
Verification of recombinant strain homogeneity was Growth of FHVb-galgIgED in CRFK tissue culture
made possible by a sensitive PCR assay. The recombi-
The complex formed by herpesvirus gI and gE hasnant was plaque purified until a 478-bp PCR assay prod-
been associated with viral FC receptor binding and pene-uct (ap in Fig. 1) unique to the parent strain was not
tration or egression properties (Dingwell et al., 1994).detected by gel electrophoresis. The PCR assay had a
However, we have not been able to demonstrate an FCdetection limit of 4 1 102 copies of purified FHV-1 geno-
receptor binding activity in FHV-1 (data not shown). Sincemic DNA, which is equal or less than 1 TCID50 , de-
the latter properties directly affect the replication rate ofpending on the level of defective interfering particles in
virus, removal of gI and gE should reduce viral replicationa preparation (Fig. 2). In addition to PCR analysis, a digox-
rate. Indeed, in experiments with other herpesvirus spe-igenin-labeled negative-strand probe specific for the re-
cies where gI and gE were deleted a small plaque pheno-gion deleted from FHVb-galgIgED failed to hybridize to
RNA isolated from FHVb-galgIgED-infected cells har-
vested after complete CPE was observed. The probe did
disclose two transcripts (Spatz, 1993), one for gG, gD,
and gI, and a smaller one for gE, described for the unique
short region when hybridized to RNA isolated from the
parent strain (data not shown).
The hemagglutinating glycoprotein of FHV-1 has been
identified as gD, an essential glycoprotein (Maeda et al.,
1994). However, an FHV-1 mutant lacking hemagglutinat-
ing ability has not yet been identified. To test the role of
gI and gE in hemagglutination, FHVb-galgIgED virions
were purified through a potassium tartrate gradient (Rota
et al., 1986) and compared by assay to similarly prepared
parent virions (Gillespie et al., 1970). Both the parent
strain and FHVb-galgIgED were hemagglutinating, sug-
gesting that neither gI nor gE plays a role in hemaggluti-
FIG. 3. Ascending chromatographic blot of restriction enzyme-di-nation.
gested virion DNA. Ten micrograms of either parent (lanes 1, 3, 5) or
recombinant (lanes 2, 4, 6) virion DNA was digested with EcoRI (lanes
Verifying the structure of the recombinant 1 and 2), HindIII (lanes 3 and 4), or SalI (lanes 5 and 6), fractionated
by electrophoresis, and blotted. A digoxigenin-labeled probe described
Virion DNA was isolated from both recombinant and under Materials and Methods, corresponding to the donor plasmid
parent strains and digested with restriction enzymes (Fig. 1), was hybridized to the blot. The blot was developed as described
and photographed. Size markers correspond to fl cut with HindIII.EcoRI, HindIII, and SalI, and the fragments were sepa-
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TABLE 2 TABLE 3
Virus Plaque Diametera Efficacy of Vaccination with the Parent and Recombinant FHV-1
Strains via the Subcutaneous Route
Virus strain
Cat Animal designation Total clinical
no. Vaccination group no. scoreaCell type Parent FHVb-galgIgED
CRFK 2.0 { 1.0 0.25 { 0.1 1 Recombinant 279 8
2 Recombinant 283 5Feline trachea 0.5 { 0.1 0.1 { 0.1
3 Recombinant 290 3
4 Recombinant 284 13a Plaque diameters are given in millimeters and are the average
measurements of 20 viral plaques. The range of measurement for 20 5 Recombinant 287 6
6 Parent 269 1plaques is given.
7 Parent 285 4
8 Parent 274 0
type resulted (Dingwell et al., 1994; Zsak et al., 1992). 9 Parent 271 0
Thus, the plaque size of the recombinant strain, FHVb- 10 Parent 272 4
11 Unvaccinated control 004 29galgIgED, was compared to that of the parent strain in
12 Unvaccinated control 002 34two different susceptible cell lines. Plaque development
13 Unvaccinated control 010 38was observed in CRFK and FT cell cultures infected at 14 Unvaccinated control 012 42
an m.o.i. of 0.01 40-hr postinfection. At this level, isolated 15 Unvaccinated control 008 33
individual plaques were clearly visible in wells infected
a Total clinical score was determined as described in U.S. Depart-with either the parent or the recombinant virus strain.
ment of Agriculture, Animal and Plant Health Inspection Service, Na-The average size of 20 plaques was determined for each
tional Animal Veterinary Services Laboratory, 1985, Table 1.culture (Table 2). In both feline trachea cells and CRFK
cells, strain FHVb-galgIgED produced plaques that aver-
strain during the exponential phase. The titer of the re-age one-fourth the size of the parent strain. This is con-
combinant stabilized approximately 1 log lower than thesistent with experimental data obtained for other herpes-
parent (Fig. 4). Furthermore, the virus titer obtained forvirus species from which the gI and gE genes were de-
FHVb-galgIgED was 6.921 106 TCID50/ml, while the par-leted.
ent strain titer was 6.4 1 107 TCID50/ml. Plaques pro-A one-step growth curve was constructed, as de-
duced by the recombinant strain were less pronouncedscribed under Materials and Methods, for both the re-
and had large syncytial centers (data not shown).combinant strain and the parent strain (Fig. 4). Virus titer
was measured at 5-hr intervals after inoculation. Follow-
Immunogenicity of FHV-1 recombinant straining the eclipse phase the titer of both the recombinant
and the parent began increasing simultaneously, but the Twenty-one and seven days prior to oronasal chal-
recombinant virus yield lagged behind that of the parent lenge with 106 TCID50 of FVR-SGE, a virulent challenge
strain provided by the USDA, two randomly chosen
groups of five specific-pathogen-free cats were inocu-
lated subcutaneously with 107 TCID50 of either the recom-
binant or the Solvay virulent parent FHV-1 strain (U.S.
Department of Agriculture, Animal and Plant Health In-
spection Service, National Animal Veterinary Services
Laboratory, 1985; Table 1). In three of five cats, subcuta-
neous inoculation of the parent strain induced clinical
signs within 2 days, consisting of ocular and nasal muco-
purulent discharge, fever, and sneezing. These signs
subsided after 3 days. Only subtle clinical signs were
observed following subcutaneous inoculation with the
recombinant. A group of five unvaccinated cats served as
the unvaccinated control group. After challenge, animals
were examined for clinical signs of disease for 14 days
as described (U.S. Department of Agriculture, Animal and
Plant Health Inspection Service, National Animal Veteri-
nary Services Laboratory, 1985; Table 1). The scores are
tabulated in Table 3 and plotted in Fig. 5 for individual
FIG. 4. One-step growth curve for FHVDgIgEbgal and the parent
animals in each of three cat treatment groups consistingstrain. Virus titer in TCID50 units is plotted versus time postinoculation.
of the recombinant and parent strain vaccinates and un-The parent strain is depicted by open squares while FHVDgIgEbgal
is depicted with filled circles. vaccinated controls.
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FIG. 5. Bar chart showing the relative response of 15 SPF cats to challenge with virulent FHV-1 after vaccination with the recombinant strain or
the parent strain or without vaccination as listed in Table 3. Clinical score represents the total scores applied for each clinical symptom appearing
during the course of infection, as described in Table 1 (U.S. Department of Agriculture, Animal and Plant Health Inspection Service, National Animal
Veterinary Services Laboratory, 1985).
Subcutaneous inoculation with a high dose of FHVb- the gI gene nor the gE gene is expressed, suggesting
galgIgED is effective in that it significantly reduces clini- that intact gI and gE genes are not essential for growth
cal signs that result from virulent virus in the control of FHV-1, as is true for other alphaherpesviruses (Balan
group (Kruskal and Wallis’ improvement of Wilcoxon’s et al., 1994). We have found the recombinant strain to be
two-sample rank test, P  0.0001; Brownlee, 1965). That completely stable and homogeneous after 12 passages.
the parent strain appears to have protected cats from The parent strain also maintained its virulence through
virulent virus challenge better than the recombinant 12 cell culture passages (Kruger et al., 1995). However,
(Kruskal and Wallis’ improvement of Wilcoxon’s two-sam- deletion of a gI–gE encoding segment of the FHV-1 ge-
ple rank test, P  0.1; Brownlee, 1965) suggests that the nome reduces virus titer in cell culture and viral plaque
recombinant did not grow as well as the parent when size in both feline trachea cells and Crandell Reese feline
administered subcutaneously. Whereas the parent strain kidney cells. PRV strains from which gE is deleted also
spread to mucosal sites (i.e., virus shedding detected by exhibit a small plaque phenotype in a cell-type-specific
oronasal swabbing), likely enhancing mucosal immunity, manner (Zsak et al., 1992). As with PRV, deletion of gE
no evidence of such spread was seen with the recombi- from FHV-1 may result in diminished cell-to-cell transmis-
nant. We are now investigating other routes of delivery to sion. Virus titers after CPE had advanced to completion
enhance recombinant immunogenicity. Details of these were reduced for the recombinant relative to the parent
trials to determine the safety and efficacy of the recombi- by approximately 1 log, even when titers were deter-
nant as an FHV-1 vaccine will be given elsewhere (Kruger mined after sonication. Recombinant virus growth rate
et al., 1995). as shown in Fig. 4 was retarded. Indeed, deletion of gE
from FHV-1 is likely to affect cell-to-cell transmission.
DISCUSSION We have shown that cats inoculated subcutaneously
with FHVb-galgIgED are protected from challenge withWe describe here the construction and isolation of
a virulent FHV-1 strain. However, vaccination with therecombinant feline herpesvirus-1 expressing b-galacto-
recombinant strain by the subcutaneous route did notsidase. Insertion of the b-galactosidase gene into FHV-
protect cats as well as vaccination with the virulent par-1 replaces the 3*-end of the gI gene, the promoter for
ent. The level of protection from virulent challenge pro-the gE gene, and a downstream portion of the gE gene.
vided by the recombinant may have been affected byConstruction of the recombinant as shown in Fig. 1 was
verified by Southern blot. Neither the deleted portion of several factors. Two immunogenic glycoproteins, gE and,
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Balan, P., Davis-Poynter, N., Bell, S., Atkinson, H., Browne, H., andpotentially, gI were removed from FHV-1 in the recombi-
Minson, T. (1994). An analysis of the in vitro and in vivo phenotypesnant. Cats only raise an immune response against the
of mutants of herpes simplex virus type 1 lacking glycoproteins gG,
remaining glycoproteins. Thus, the lack of a subset of gE, gI, or the putative gJ. J. Gen. Virol. 75, 1245–1258.
circulating memory B-cells recognizing gI and gE may Banks, T. B., and Rouse, B. T. (1991). Herpesviruses—immune escape
influence virus neutralization. Another factor may be artists? Clin. Infect. Dis. 14, 933–941.
Bistner, S. I., Carlson, J. H., Shively, J. N., and Scott, F. W. (1971). Ocularthe route of inoculation. The preferred route of inocula-
manifestations of feline herpesvirus infection. J. Am. Vet. Med. Assoc.tion used by veterinarians for vaccination against FHV-
159, 1223–1237.1 is subcutaneous. Clinical signs induced by the parent
Brownlee, K. A. (1965). ‘‘Statistical Theory and Methodology in Science
strain are evidence of spread of this strain to mucosal and Engineering.’’ Wiley, New York.
sites where mucosal immunity would be induced. Sec- Burgener, D. C., and Maes, R. K. (1988). Glycoprotein-specific immune
responses in cats after exposure to feline herpesvirus-1. Am. J. Vet.ondary replication in the oronasal cavity may also be
Res. 49, 1673–1676.responsible for better protection. Administration of the
Crandell, R. A. (1971). Virologic and immunologic aspects of felinerecombinant by the subcutaneous route would likely
rhinotracheitis virus. J. Am. Vet. Med. Assoc. 158, 922–926.bypass the induction of mucosal immunity, since no
Crandell, R. A., and Maurer, F. D. (1958). Isolation of a feline virus
secondary replication occurs in the oronasal cavity associated with intranuclear inclusion bodies. Proc. Soc. Exp. Biol.
with this strain (Kruger et al., 1995). The replicative Med. 97, 487–490.
Davis, E. V., and Beckenhauer, W. H. (1976). Studies on the safety andability of either the parent or the recombinant strain at
efficacy of an intranasal feline rhinotracheitis-calici virus vaccine.the site of inoculation ultimately determines the level
Vet. Med. Small Anim. Clin. 10, 1405–1410.of mucosal immunity.
Dingwell, K. S., Brunetti, C. R., Hendricks, R. L., Tang, Q., Tang, M.,
Because gE and gI have a role in cell-to-cell spread, Rainbow, A. J., and Johnson, D. (1994). Herpes simplex virus glycopro-
their double deletion would reduce viral spread after in- teins E and I facilitate cell-to-cell spread in vivo and across junctions
of cultured cells. J. Virol. 68, 834–845.oculation and the number of antigen-bearing particles
Ditchfield, J., and Grinyer, I. (1965). Feline rhinotracheitis virus: A felinepresented to the immune system (i.e., presentation to
herpesvirus. Virology 26, 504–506.circulating and mucosal immune cells). Since the parent
Edwards, B. G., Buell, D. J., and Acree, W. M. (1977). Evaluation of astrain is not hindered in either virus spread or virus repli-
new feline rhinotracheitis virus vaccine. Vet. Med. Small Anim. Prac.
cation, a more effective immune response would be 11, 205–209.
mounted against the parent than the recombinant. After Enquist, J., Dubin, J., Whealy, M. E., and Card, J. P. (1994). Complementa-
tion analysis of pseudorabies virus gE and gI mutants in retinalinoculation with parent, animals may then be left with a
ganglion cell neurotropism. J. Virol. 68, 5275–5279.larger memory cell population, including both mucosal
Enquist, L. W. (1994). Infection of the mammalian nervous system byand circulating cells. Thus, the best subcutaneous vac-
pseudorabies virus (PRV). Semin. Virol. 5, 221–231.
cine in terms of protection against virulent challenge may Fawl, R. L., and Roizman, B. (1994). The molecular basis of herpes
be a virulent strain. However, there are disadvantages simplex pathogenicity. Semin. Virol. 5, 261–271.
to using virulent or semivirulent strains as modified live Feldman, L. T. (1994). Transcription of the HSV-1 genome in neurons
in vivo. Semin. Virol. 5, 207–212.vaccines. Primarily, the vaccine itself may cause signifi-
Fitzpatrick, D. R., and Bielefeldt-Ohmann, H. (1991). Mechanism of her-cant disease after vaccination if not properly adminis-
pesvirus immuno-evasion. Microb. Pathog. 10, 253–259.tered (Stanley and Jabara, 1988). Furthermore, a virulent
Gaskell, R., and Povey, R. C. (1982). Transmission of feline rhinotra-
vaccine strain under some circumstances may be reacti- cheitis. Vet. Rec. 111, 359–362.
vated after inoculation, allowing the vaccinee to spread Gaskell, R. M. (1993). Upper respiratory disease in the cat (including
virulent virus to other animals. The advantage in using chlamydia): Control and prevention. Feline Pract. 21, 29–34.
Gaskell, R. M., and Povey, R. C. (1979). Feline viral rhinotracheitis:a generation II modified live vaccine is that even with
Sites of virus replication and persistence in acutely and persistentlyreactivation, no virulent virus will be shed.
infected cats. Res. Vet. Sci. 27, 167–174.
Geballe, A. P., Spaete, R. R., and Mocarksi, E. S. (1986). A cis-acting
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